Cavalier Jason, CFO of Lyra Therapeutics ($LYRA), made two open market sales of company shares in the past year, totaling $8,681. His most recent sale occurred on January 6, 2026. These transactions rank 11,299th among 11,678 insiders in our database, well below the average of $8.6 million per insider across about six sales. He recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Principal Financial Officer | D | Common Stock | 667 | $0.00 | 517,880.0000 | 1,774,882 | 0.13% | 0.04% |
| Jan. 6, 2026 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Chief Financial Officer | S | Common Stock | 769 | $3.36 | 518,547.0000 | 1,774,882 | 0.15% | 0.04% |
| July 10, 2025 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Chief Financial Officer | S | Common Stock | 684 | $8.91 | 519,316.0000 | 65,880,561 | 0.13% | 0.00% |
| Jan. 8, 2025 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Chief Financial Officer | A | Common Stock | 420000 | $0.00 | 520,000.0000 | 0 | 420.00% | 0.00% |
| Oct. 16, 2024 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Chief Financial Officer | A | Common Stock | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 30, 2024 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Chief Financial Officer | A | Stock Options | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2023 | Lyra Therapeutics, Inc. | $LYRA | Cavalier Jason | Chief Financial Officer | A | Stock Option | 140000 | $0.00 | 140,000.0000 | 0 | 9999.99% | 0.00% |